Whalesbook
### Domestic Demand Powers Pharma Sector Surge
The Nifty Pharma index has demonstrated impressive strength in February 2026, advancing 7% and nearing its 52-week high of 23,492.55 reached on January 7, 2026. This performance stands in stark contrast to the Nifty 50's modest 0.56% gain for the month, highlighting the pharmaceutical sector's distinct upward trajectory. On Thursday, the index climbed nearly 1%, outpacing a generally subdued market where the Nifty 50 saw a marginal decline.
### Q3 FY26 Results Showcase Sectoral Resilience
The robust performance is underpinned by strong financial results for the December 2025 quarter (Q3 FY26), where the pharmaceutical sector reported a 12.3% year-on-year growth. This expansion was largely propelled by India's domestic market, which grew by 12% year-on-year, driven by demand for chronic therapies and the sustained momentum of GLP-1 drugs such as Tirzepatide and Semaglutide. While revenue from the United States experienced some softening due to reduced sales of gRevlimid, companies like Lupin and Dr. Reddy's Laboratories managed to deliver healthy results, thereby mitigating the impact of generic market pressures.
### Analyst Outlook: A Mixed Bag of Opportunity and Caution
Looking ahead, the sector is poised for continued growth, driven by a strong pipeline in biosimilars, non-US semaglutide, and peptide-based therapeutics over the next three years. Companies with a significant focus on domestic chronic portfolios and innovative drug development are expected to lead the pack. However, a critical note of caution arises as Q3 FY26 marks the final quarter of exclusivity for gRevlimid. The product's patent expiry in January 2026 signals potential near-term pressure on growth and margins for companies heavily exposed to this drug, as highlighted by analysts at ICICI Securities.
### Individual Stock Performance and Valuations
Among individual stocks, Mankind Pharma saw a significant intra-day rally of 6%. Other notable performers included Zydus Lifesciences, Glenmark Pharmaceuticals, Alkem Laboratories, Laurus Labs, Aurobindo Pharma, Lupin, and Dr. Reddy's Laboratories, each posting gains between 1% and 2%.
Several brokerages have shared their views on key players. Sun Pharmaceutical Industries is undergoing a strategic shift from low-margin generics to high-value specialty and innovative therapies in the US market, alongside growth prospects in emerging markets and its domestic stronghold. Mirae Asset Sharekhan maintains a 'Buy' rating on Sun Pharma with a target price of ₹1,968, citing its low leverage and healthy cash flows, valuing the stock at 34x its FY28E earnings per share. Divi's Laboratories also holds a 'Buy' recommendation from Mirae Asset Sharekhan, with a target of ₹7,206, driven by anticipated improvements in its Contract Development and Manufacturing Organization (CDMO) business, despite a marginal trim in growth estimates. Lupin has raised its FY26E EBITDA margin guidance for the second consecutive quarter to 27-28%. BNP Paribas India, while maintaining a 'Neutral' rating and a target price of ₹2,490, anticipates Lupin will benefit from delayed competition and litigation settlements, though it forecasts a medium-term taper in US sales that could affect margins.
### The Analytical Deep Dive: Valuations and Competitive Positioning
The pharmaceutical sector currently exhibits a P/E ratio of approximately 33.87, with individual stock valuations varying significantly. Sun Pharmaceutical Industries trades at a P/E of 34.7, while Dr. Reddy's Laboratories is at 19.80, and Aurobindo Pharma at 20.07. Lupin's P/E stands at 22.44, and Mankind Pharma at 49.51. Laurus Labs shows a significantly higher P/E of 69.01, contrasting with Divi's Laboratories at 66.99. These P/E ratios suggest that while some companies like Dr. Reddy's and Aurobindo are trading at more moderate multiples, others like Laurus Labs and Divi's Laboratories are priced at a premium, reflecting higher growth expectations or specialized market positions.
### The Hedge Fund View: Margin Pressures and Regulatory Scrutiny
Despite the overall positive sentiment, the sector faces potential headwinds. The impending loss of gRevlimid exclusivity, effective from January 2026, presents a tangible risk to near-term revenue and profit margins for companies reliant on this drug. This shift away from blockbuster generics towards specialty products, while strategically sound, introduces a period of adjustment. Furthermore, the US generics market continues to exert pressure. Divi's Laboratories, despite strong fundamentals, operates with high earnings multiples, with an expected P/E of 65.05 for the current fiscal year. Its "enterprise value to sales" ratio is also noted as being among the highest globally, indicating that its valuation is rich relative to its tangible assets and cash flows. While analysts have revised opinions upwards for Divi's, the high valuation demands sustained performance to justify investor expectations.
### Future Outlook: Innovation and Diversification
The pharmaceutical sector's future growth trajectory appears to be tied to its ability to innovate and diversify its product portfolio. A strong pipeline in biosimilars, novel drug delivery systems, and specialized therapies is crucial for navigating the evolving market dynamics and offsetting the decline in traditional generics. Companies that successfully manage the transition to specialty products, coupled with a robust domestic presence, are likely to outperform. Analyst targets, such as the ₹1,968 set by Mirae Asset Sharekhan for Sun Pharma, reflect confidence in sustained profitability driven by this strategic pivot.